BTC Health Ltd (ASX: BTC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
BTC Health Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$25.02 million
P/E Ratio
5.76
Dividend Yield
0.00%
Shares Outstanding
357.45 million
Earnings per share
0.012
Dividend per share
N/A
Year To Date Return
9.68%
Earnings Yield
17.35%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
BTC Health Ltd (ASX: BTC)
Latest News
⏸️ Investing
6 listed funds with tax free capital gains and dividends
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 05 Jul 2011 | $0.0280 | 0.00% | Special Cash | 15 Jul 2011 |
| 03 Sep 2010 | $0.0140 | 0.00% | Final | 13 Sep 2010 |
BTC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About BTC Health Ltd
BTC Health Ltd is a pooled development fund focused on seeking new investment opportunities in entities operating in the biotechnology and life sciences sectors. Its sole operating segment involves making and managing healthcare ventures. The company's products include Elasto-Q, Rythmic Infusion Pumps, Tiva, Infusion and Nerve Catheter Kits, Biopsy Needles, Radiological Markers, Rebellion Bone Removal System, Bonopty Coaxial Bone Biopsy, ECLS (Extracorporeal Life Support) Oxygenators, Pears, Valves, NEOLA, and LPS Adsorber. Geographically, it operates in Australia.
BTC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 12 Feb 2026 | $0.07 | $0.00 | 0.00% | 194,519 | $0.07 | $0.07 | $0.07 |
| 11 Feb 2026 | $0.07 | $0.00 | 0.00% | 15,384 | $0.07 | $0.07 | $0.07 |
| 10 Feb 2026 | $0.07 | $0.00 | 0.00% | 53,118 | $0.07 | $0.07 | $0.07 |
| 09 Feb 2026 | $0.07 | $0.00 | 0.00% | 25,000 | $0.07 | $0.07 | $0.07 |
| 06 Feb 2026 | $0.07 | $0.00 | 0.00% | 290,742 | $0.07 | $0.07 | $0.07 |
| 04 Feb 2026 | $0.07 | $0.00 | 0.00% | 30,123 | $0.07 | $0.07 | $0.07 |
| 03 Feb 2026 | $0.06 | $0.00 | 0.00% | 14,335 | $0.06 | $0.06 | $0.06 |
| 02 Feb 2026 | $0.06 | $0.00 | 0.00% | 25,813 | $0.06 | $0.06 | $0.06 |
| 30 Jan 2026 | $0.06 | $0.00 | 0.00% | 20,679 | $0.06 | $0.06 | $0.06 |
| 28 Jan 2026 | $0.06 | $0.00 | 0.00% | 83,727 | $0.06 | $0.06 | $0.06 |
| 23 Jan 2026 | $0.06 | $0.00 | 0.00% | 8,250 | $0.06 | $0.06 | $0.06 |
| 22 Jan 2026 | $0.06 | $0.00 | 0.00% | 26,400 | $0.06 | $0.06 | $0.06 |
| 21 Jan 2026 | $0.06 | $0.00 | 0.00% | 4,000 | $0.06 | $0.06 | $0.06 |
| 20 Jan 2026 | $0.07 | $0.00 | 0.00% | 35,028 | $0.07 | $0.07 | $0.07 |
| 19 Jan 2026 | $0.07 | $0.00 | 0.00% | 3,000 | $0.07 | $0.07 | $0.07 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 24 Jun 2025 | Richard Treagus | Buy | 319,939 | $16,636 |
On-market trade.
|
| 24 Jun 2025 | Martin Kahanovitz | Buy | 3,850,000 | $200,200 |
On-market trade.
|
| 19 Mar 2025 | Richard Treagus | Buy | 118,546 | $6,285 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Richard Spencer Treagus | Executive ChairmanExecutive Director | Aug 2014 |
Dr Treagus is an entrepreneur with over 25 years' experience in all aspects of the international pharmaceutical and biotechnology industry. Formerly a Director of Neuren Pharmaceuticals Limited.
|
| Ms Felicity McNeill | Non-Executive Director | Oct 2022 |
Ms. McNeill is a senior executive with 25 years' experience across the public and private sector including almost 15 years in the regulatory and subsidy systems for medicines, vaccines, devices and diagnostics in Australia. Appointed 10 October 2022.
|
| Mr Martin Kahanovitz | Non-Executive Director | Jun 2025 |
Mr Kahanovitz is Chief Financial Officer of the Kahma Healthcare Group and also serves as Director for The Biologicals and Vaccine Institute of Southern Africa (Pty) Ltd t/a Biovac and as Chairperson for the Finance and Risk Board Committee. Mr. Kahanovitz is a registered Director with nearly 30 years of professional experience in the biotechnology, pharmaceutical, and medical industries.
|
| Mr Salesh Balak | Chief Financial OfficerCompany Secretary | Mar 2025 |
-
|
| Salesh Balak | Chief Financial OfficerCompany Secretary |
-
|
|
| J Kahanovitz | Chief Operating Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 93,087,758 | 28.61% |
| Mrs Karen Elizabeth Treagus | 30,000,000 | 9.22% |
| Sigma Company Limited | 16,856,467 | 5.18% |
| Namarong Investments Pty Ltd | 15,000,000 | 4.61% |
| Kingfisher Medical Pty Ltd | 14,092,318 | 4.33% |
| Glk Medical Pty Ltd | 14,092,318 | 4.33% |
| Tau Investments Australia Pty Ltd | 14,092,318 | 4.33% |
| Mr Thomas Christopher Fennell | 8,682,787 | 2.67% |
| Sigma Company Limited i | 8,143,533 | 2.50% |
| Mr Campbell Dinwoodie Taylor | 7,985,024 | 2.45% |
| Argus Nominees Pty Ltd | 5,500,000 | 1.69% |
| Mrs Susan Maree Whiting | 5,000,000 | 1.54% |
| Windarri Investments Pty Ltd | 4,213,727 | 1.30% |
| HSBC Custody Nominees (Australia) Limited | 4,206,000 | 1.29% |
| Mr Nicholas Dermott Mcdonald | 4,204,791 | 1.29% |
| Mr Martin Michael Kahanovitz | 3,850,000 | 1.18% |
| Abeille Investments Pty Limited | 3,800,000 | 1.17% |
| Sigma Company Limited ii | 3,627,553 | 1.12% |
| Namarong Investments Pty Ltd i | 3,125,000 | 0.96% |
| Linwierik Investments Pty Ltd | 2,600,000 | 0.80% |
| Chanuk Nominees Pty Ltd | 2,000,000 | 0.61% |
| Pritdown Pty Ltd | 2,000,000 | 0.61% |
| Mr Oskar Hakansson | 1,798,758 | 0.55% |
